重庆钢铁提示，本次向特定对象发行A股股票尚需公司股东会及类别股东会审议，并经股东会审议豁免 A股全面要约义务、经股东会审议H股清洗豁免并经香港证券及期货事务监察委员会的批准（认购方保 留经中国宝武批准豁免该项生效条件的权利）、上海证券交易所审核通过并经中国证监会同意注册后方 可实施。 1月4日晚间，重庆钢铁股份有限公司（以下简称"重庆钢铁"）发布公告称，近日，公司收到实际控制人 中国宝武钢铁集团有限公司（以下简称"中国宝武"）《关于重庆钢铁向特定对象发行A股股票的批 复》，中国宝武原则同意公司向特定对象发行A股股票方案。 据悉，2025年12月19日晚间，公司公布2025年度向特定对象发行A股股票预案，拟向实控人中国宝武旗 下金融投资平台——华宝投资有限公司（简称"华宝投资"）定增约7.58亿股，发行价格1.32元/股，募集 资金不超过10亿元，扣除发行费用后将全部用于补充流动资金及偿还银行贷款。 重庆钢铁表示，本次发行将有助于进一步改善上市公司流动性水平，优化资本结构，提高上市公司的总 资产和净资产规模，降低上市公司的资产负债率和财务费用，提升上市公司的抗风险能力，同时亦符合 国家提高直接融资比重、增强金融 ...

【大河财立方 记者 王时丹】当2025年的日历翻至最后一页，全国A股融资地图清晰呈现：全年股权融 资规模超万亿元，长三角、珠三角及环渤海地区持续领跑，北京、上海年内股权融资规模突破千亿元。 | | | | | | 单位:亿元 | | --- | --- | --- | --- | --- | --- | | 序号 | 省(直辖市) | 总额 | 首发 | 增发 = | 可转债发行 | | 1 | 北京 | 4.585.07 | 199. 08 | 4,362. 45 | 11 23. 54 | | 2 | 上海 | 1.858.17 | 96. 71 | 1.727.91 | 33. 55 | | 3 | 广东 | 984. 90 | 182. 70 | 559. 56 | 242. 65 | | 4 | 江苏 | 775.61 | 200. 95 | 506. 37 | 68. 29 | | 5 | 重庆 | 365. 90 | NE | 317. 40 | 48. 50 | | 6 | · 福建 | 328. 40 | 224. 47 | 47.99 | 55. 94 | | 7 | 浙江 | 321. ...

本次发行的股票种类为境内上市的人民币普通股（A股），每股面值为人民币1.00元。本次发行的 股票将在深圳证券交易所主板上市交易。本次发行的股票数量按照募集资金总额除以发行价格最终确 定，且不超过本次发行前公司总股本的30%，即不超过99,556,080股（含本数）。 本次向特定对象发行股票募集资金总额不超过人民币197,000.00万元（含本数），扣除发行费用后 的募集资金净额将用于起降系统产能扩建项目、民航产品产业化项目、民航大飞机适航保障能力提升项 目、 补充流动资金。 本次向特定对象发行股票的定价基准日为发行期首日，发行价格不低于定价基准日前二十个交易日 公司股票交易均价的百分之八十。 中国经济网北京12月30日讯 北摩高科(002985.SZ)昨晚披露2025年度向特定对象发行A股股票预 案，本次向特定对象发行股票的发行对象不超过35名（含），为符合中国证监会规定条件的特定投资 者，包括符合规定条件的证券投资基金管理公司、证券公司、信托公司、财务公司、保险机构投资者、 合格境外机构投资者，以及符合中国证监会规定的其他法人、自然人或其他合格的投资者。其中，证券 投资基金管理公司、证券公司、合格境外机构投 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：证券之星 昔日影视巨头华谊兄弟（300027.SZ）正身陷多重危机。近日公司披露，公司股东杭州阿里创业投资有 限公司（以下简称"阿里创投"）通过大宗交易方式减持1.064%公司股份。阿里创投及其一致行动人马云 不再是公司持股5%以上股东。阿里创投减持时点正值华谊兄弟控股股东、实控人王忠军所持5.55%股份 将被司法拍卖前夕，加剧了市场对上市公司控制权稳定性和发展前景的担忧。 证券之星注意到，在阿里创投减持背后，受影视行业持续调整和早前激进扩张留下的"后遗症"拖累，华 谊兄弟自2018年以来扣非后净利润持续亏损。今年前三季度，公司业绩再度严重亏损。业绩连亏下，华 谊兄弟流动性已严重不足。截至今年三季度末，公司资产负债率攀升至87.69%，短债缺口超13亿元。 在定增融资事项筹划多年仍推进缓慢的背景下，公司近几年频频出售旗下资产以回笼资金，但仍难以完 全填补窟窿。近日华谊兄弟公告，公司合计已有5250万元债务逾期。此外，公司在多家银行开立的多个 账户已被冻结。如债务危机持续发酵，恐进一 ...

中国经济网北京12月16日讯据上交所网站15日消息，浙江福莱新材（605488）料股份有限公司(简称"福莱新材"，605488.SH)非公开发行股票审核状态为通 过。 | 上市公司全称 | 浙江福莱新材料股份有限公司 | 上市公司简称/ 扩位简称 | 福莱新材/- | | --- | --- | --- | --- | | 上市公司代码 | 605488 | 再融资方式 | 非公开发行股票 | | 融资金额(亿元) | 7.10 | 受理日期 | 2025-10-28 | | 审核状态 | 通过 | 更新日期 | 2025-12-15 | 福莱新材10月28日披露的向特定对象发行股票募集说明书(申报稿)显示，本次发行募集资金总额不超过人民币71,000.00万元(含本数)，扣除相关发行费用后 的募集资金净额拟用于标签标识印刷材料扩产项目、电子级功能材料扩产升级项目、研发中心升级项目和补充流动资金。 | | | | 单位:万元 | | --- | --- | --- | --- | | 序号 | 项目名称 | 项目投资总额 | 拟使用募集资 金投入金额 | | 1 | 标签标识印刷材料扩产项目 | 28.932 ...

美迪凯（688079.SH）子公司再次增资引入战投。 长江商报消息●长江商报记者 徐佳 光学半导体公司原本为美迪凯的全资子公司。 2024年6月，光学半导体公司实施增资扩股引入战略投资者服务贸易创新发展引导基金（有限合伙） （以下简称"服贸基金"）。 上述增资中，光学半导体公司的投前估值为18亿元，服贸基金以1.9823元对应每一元注册资本的价格， 向光学半导体公司投资2亿元，取得增资后光学半导体公司10%的股权。 资料显示，服贸基金的执行事务合伙人为招商局资本管理（北京）有限公司，主要出资方包括江苏省财 政厅实控的江苏疌泉服务贸易产业投资基金、财政部、招商局金控旗下深圳市招服投资有限责任公司 等。 时隔一年，光学半导体公司将再次增资引入战投。12月10日晚间，美迪凯披露增资计划，光学半导体公 司拟以增资扩股的方式引进战略投资者富浙绍芯。 12月10日晚间，美迪凯披露子公司增资计划，公司控股子公司浙江美迪凯光学半导体有限公司（以下简 称"光学半导体公司"）拟增资扩股，战略投资者浙江富浙绍芯集成电路产业基金合伙企业（有限合伙） （以下简称"富浙绍芯"）拟以现金2亿元对光学半导体公司增资。 长江商报记者注意到，富 ...

目前，新疆融能所持国际实业股份质押率达70%。而根据国际实业问询函回复，新疆融能全额认购本次 6.62亿元定增资金来源为，自有资金6190万元、自筹资金6亿元，自筹资金主要通过股票质押借款以及 银行借款的途径获取。 国际实业经营业绩并不理想。2024年，公司亏损4.39亿元，2025年前三季度盈利数仅为0.20亿元。过去 四年，公司未曾派发现金红利。 向大股东定增募资曾两度夭折 长江商报消息●长江商报记者 沈右荣 易主之后，国际实业（000159.SZ）首次进行再融资。 12月8日晚，国际实业披露定增说明书（申报稿），公司拟向控股股东新疆融能投资发展有限公司（以 下简称"新疆融能"）发行股票，募资不超过6.62亿元，所募资金全部用于补充流动资金。 针对本次定增，深交所下发了问询函，对国际实业经营业绩稳定性、应收账款、预付账款、商誉、发行 对象资金来源等多个方面问题进行了问询。12月8日，公司对此进行了回复。 2025年7月，国际实业"0元易主"，公司控股股东未变，实际控制人由冯建方变更为冯现啁，二人为兄弟 关系。 长江商报记者发现，2022年，国际实业就筹划向控股股东江苏融能（2024年12月更名为新疆融能） ...

Core Viewpoint - The company is focused on long-term development in the blueberry industry, with a recent fundraising initiative aimed at expanding its operations and enhancing its organizational capabilities [2][3]. Group 1: Fundraising and Financial Performance - The company plans to use 85% of the funds from the upcoming private placement for the construction of blueberry bases and research centers, indicating a commitment to its core business [2]. - The recent performance of the company's funds shows a strong return, with the best-performing fund, "泉果旭源三年持有期混合A," achieving a return of 33.35% over the past year [1][2]. Group 2: Management and Operational Strategies - The company's actual controller's recent share reduction is aimed at clearing historical stock pledge loans, allowing for a more focused management approach [4]. - The new production season has started well, with shipment progress meeting or slightly exceeding expectations, and overall prices remaining stable [5][6]. Group 3: Brand Development and Market Expansion - The company has designated the current production season as the "Brand Year," focusing on the "爱莓庄" brand and ensuring high-quality output from the production source [7]. - Collaborations with key customers, such as Hema, have led to significant increases in supply volume, enhancing brand recognition [7]. Group 4: Future Growth Drivers and Cost Control - Future growth is expected to come from three areas: land expansion for increased capacity, efficiency improvements through aging trees and technology optimization, and variety optimization by upgrading outdated seedlings [8]. - The company is implementing measures to control costs, focusing on post-harvest costs and middle-office expenses through organizational adjustments and efficiency improvements [8]. Group 5: Land Acquisition and R&D Center - The company is confident in acquiring high-quality contiguous land in Yunnan, leveraging its long-standing industry experience and government relations [8]. - The "Small Berry International Research Center" will focus on breeding research and improving production efficiency, addressing practical production issues through technological innovation [8].

Core Viewpoint - The company, Sungrow Power Supply Co., Ltd., has received approval for a private placement to raise 1.65 billion yuan, which will be used for the industrialization of photovoltaic inverters and energy storage converters, but the reduction in fundraising and project scope raises concerns about the rationality of the expansion plan [1][5][12]. Financial Performance - In the first three quarters of the year, the company reported a revenue of 3.565 billion yuan, a year-on-year increase of 16.15%, while the net profit attributable to shareholders was 311 million yuan, up 2.99%, indicating a significant slowdown in profit growth compared to revenue [13]. - The third quarter alone saw revenue of 1.38 billion yuan, with a year-on-year decline in net profit of 21.88% [13]. Debt and Financing Concerns - Despite multiple rounds of financing, the company's debt ratio remains above 70%, significantly higher than comparable companies, leading to skepticism about the true purpose of the fundraising efforts [2][8][12]. - The recent fundraising amount was reduced from 2.55 billion yuan to 1.65 billion yuan, a decrease of 35%, and the scope of the projects was also narrowed [5][12]. Production Capacity and Utilization - The company's production capacity utilization rates for distributed string inverters and energy storage converters are projected to drop dramatically from over 500% to below 50% after the expansion, indicating a potential oversupply situation [10][11]. - The planned capacity utilization rates for 2024 and the first half of 2025 are expected to be 370.53% and 536.55% for distributed string inverters, and 666.26% and 272.79% for energy storage converters, respectively [10]. Cost and Margin Issues - The company's gross margin is consistently lower than that of comparable firms, and rising sales and financial expenses, along with credit impairment losses, have negatively impacted profitability [3][15]. - The inventory impairment provision has been notably low, raising concerns about product competitiveness and the economic viability of the expansion projects [4][16].

Core Viewpoint - The capital operation of Mengke Pharmaceutical, known as the "first stock of antibiotics," has been terminated after nearly two months of intense negotiations and opposition from major shareholders, particularly Genie Pharma, regarding a proposed private placement of 1.033 billion yuan [1][2][8]. Group 1: Termination of Capital Operation - On November 17, Mengke Pharmaceutical announced the termination of its plan to issue shares to specific investors due to ongoing opposition from its major shareholder Genie Pharma, which created significant disagreements with other shareholders and management [1][8]. - The company stated that continuing with the stock issuance could negatively impact its stable operational development [1][8]. Group 2: Financial Performance and Background - Mengke Pharmaceutical has faced financial difficulties, reporting net losses of 220 million yuan, 421 million yuan, and 441 million yuan from 2022 to 2024, with a net loss of approximately 194 million yuan in the first three quarters of this year [2][3]. - As of June 30, the company had only 237 million yuan in cash and cash equivalents, prompting a change in the use of IPO funds to supplement working capital [3]. Group 3: Strategic Importance of the Proposed Investment - The proposed investment from Nanjing Haiqing Pharmaceutical was seen as strategically significant for Mengke Pharmaceutical, as it could enhance production and research capabilities, reduce costs, and support project commercialization with approximately 1 billion yuan in funding [3][4]. Group 4: Shareholder Disputes - The major shareholder Genie Pharma opposed the private placement, citing concerns over the uncertainty of Haiqing Pharmaceutical's involvement, potential impacts on the company's independence, and the lack of direct operational experience in the infection treatment field [6][7]. - Genie Pharma's opposition escalated to a direct power struggle over the control of the board, with proposals to remove existing directors and replace them with individuals closely associated with Genie Pharma [7][8].